title: Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases.
abstract: BACKGROUND
  Optimal chemotherapeutic regimen in thymic carcinoma remains uncertain and the efficacy of second line chemotherapy has not been established either.
  
  
  METHODS
  We retrospectively evaluated the efficacy of an irinotecan plus cisplatin or carboplatin (IP) regimen as a salvage treatment for patients with unresectable thymic carcinoma that progressed after cisplatin, doxorubicin, vincristine and cyclophosphamide (ADOC) chemotherapy. Seven patients with histologically confirmed thymic carcinoma that was resistant to or who had relapsed after initial chemotherapy with ADOC were treated with IP. The treatment consisted of irinotecan (CPT-11, 60 mg/m2, days 1, 8 and 15) and cisplatin (80 mg/m2, day 1) or carboplatin (AUC 4) intravenously every 4 weeks, for at least 2 cycles.
  
  
  RESULTS
  Two patients achieved partial responses. Although another two patients showed a significant reduction of the primary thoracic lesion, the appearance of a new lesion was found in one and a metastatic lesion was unchanged in the other. Neutropenia over grade 3 was observed in all patients but none of the patients developed serious infections. There were no severe non-hematological toxicities, including diarrhea.
  
  
  CONCLUSIONS
  We conclude that salvage chemotherapy may be useful in certain patients with thymic carcinoma and irinotecan may be a novel and alternative agent for relapsed thymic carcinoma.
authors: First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1, Asahi Matsumoto, Japan.
authors: Shintaro
authors: S
authors: Kanda
authors: Tomonobu
authors: T
authors: Koizumi
authors: Yoshimichi
authors: Y
authors: Komatsu
authors: Sumiko
authors: S
authors: Yoshikawa
authors: Mitsuyo
authors: M
authors: Okada
authors: Orie
authors: O
authors: Hatayama
authors: Masanori
authors: M
authors: Yasuo
authors: Kenji
authors: K
authors: Tsushima
authors: Kazuhisa
authors: K
authors: Urushihata
authors: Keishi
authors: K
authors: Kubo
authors: Mari
authors: M
authors: Sasabayashi
authors: Akemi
authors: A
authors: Takamizawa
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D013953:Thymus Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D000077146:Irinotecan; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D002945:Cisplatin; D002166:Camptothecin